Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRESERVE: Bladder Preservation With Enfortumab Vedotin Plus Pembrolizumab in Muscle-Invasive Urothelial Cancer
NCT07822373Phase 2Not yet recruiting
- Sponsor
- University of Utah
- Start
- Nov 2026
- Primary completion
- Nov 2034
- Countries
- 1
01
Overview
A Phase 2 trial of enfortumab vedotin, pembrolizumab in bladder urothelial carcinoma, sponsored by University of Utah. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
enfortumab vedotinpembrolizumab
03
Conditions
bladder urothelial carcinoma
Beyond the preview
Go deeper on NCT07822373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07822373.